We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Collegium Pharmaceutical Inc (COLL) USD0.001

Sell:$15.54 Buy:$15.55 Change: $0.41 (2.57%)
NASDAQ:2.68%
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Sell:$15.54
Buy:$15.55
Change: $0.41 (2.57%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Sell:$15.54
Buy:$15.55
Change: $0.41 (2.57%)
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company focused on pain management. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

Contact details

Address:
100 Technology Center Dr
STOUGHTON
02072-4710
United States
Telephone:
+1 (781) 7133699
Website:
www.collegiumpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
COLL
ISIN:
US19459J1043
Market cap:
$526.25 million
Shares in issue:
33.97 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Heffernan
    Chairman of the Board
  • Joseph Ciaffoni
    President, Chief Executive Officer, Director
  • Colleen Tupper
    Chief Financial Officer, Executive Vice President
  • Shirley Kuhlmann
    Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
  • Scott Dreyer
    Executive Vice President, Chief Commercial Officer
  • Thomas Smith
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.